AI has been touted as a tool to streamline drug R&D, which can cost $2.6 billion and take up to 15 years, according to the Journal of Medicinal Chemistry.
But whether AI will actually develop better drugs remains an open and complicated question. To date, few AI drugs have reached clinical trials. Those that have tend to see more success in phase 1 than traditional drugs. However, that advantage might not hold up in additional testing.
The space has also been marked by high-profile setbacks, including Verge Genomics’s AI-identified ALS candidate, VRG50635, which failed to move beyond an early-stage trial.
While the overall picture is still emerging, a few closely-watched candidates offer some real-world insights into how AI-developed drugs are performing.
Insilico’s leading candidates
